ORGANIZATION
JPMA to Commit to Growth of Research-Driven Pharma Industry, R&D of COVID-19 Drugs, Vaccines: Director General
Junichi Shiraishi, director general of the Japan Pharmaceutical Manufacturers Association (JPMA), expressed his commitment, saying, “When I was appointed, I hadn’t been involved with the pharmaceutical industry for quite some time, so I wasn’t sure I was the right person…
To read the full story
Related Article
ORGANIZATION
- Labor Group Urges Priority Supply of Petrochemical Products for Drug Manufacturing
May 15, 2026
- JPMA Launches New Legal Entity, Set for October Transition
May 1, 2026
- Regional Formularies Seen Driving Shift to Quality, Industry Consolidation: Society Head
April 27, 2026
- JPMA Mulls Proposal to Standardize PMDA Review Reports
April 27, 2026
- JPWA Urges Caution on Fixed Margins, Citing French Model Shortcomings
April 24, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





